Genetic variability in CYP3A5 and its possible consequences

Pharmacogenomics

Volumn 5, Issue 3, 2004, Pages 243-272

  Xie, Hong Guang ^a   Wood, Alastair J J ^a   Kim, Richard B ^a   Stein, C Michael ^a   Wilkinson, Grant R ^a  

^a VANDERBILT UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

CYP3A4; CYP3A5; Ethnic diversity; Molecular genetic epidemiology; Pharmacogenetics; Pharmacogenomics; Polymorphism; Population genetics

Indexed keywords

ALPHA HYDROXYMIDAZOLAM; ANDROSTANOLONE; BENZODIAZEPINE DERIVATIVE; CALCINEURIN INHIBITOR; CALCIUM CHANNEL BLOCKING AGENT; CYCLOSPORIN; CYTOCHROME P450 3A4; CYTOCHROME P450 3A5; DIHYDROPYRIDINE DERIVATIVE; DRUG METABOLIZING ENZYME; GLYCOPROTEIN P; MIDAZOLAM; NIFEDIPINE; RIFAMPICIN; TACROLIMUS; TESTOSTERONE;

DNA POLYMORPHISM; DRUG BIOAVAILABILITY; DRUG BLOOD LEVEL; DRUG CLEARANCE; DRUG HYDROXYLATION; DRUG METABOLISM; GENE EXPRESSION; GENE FUNCTION; GENETIC VARIABILITY; GENOTYPE; GENOTYPE PHENOTYPE CORRELATION; HUMAN; IN VITRO STUDY; IN VIVO STUDY; NUCLEOTIDE SEQUENCE; PROTEIN EXPRESSION; PROTEIN STRUCTURE; REVIEW;

ANIMALS; ARYL HYDROCARBON HYDROXYLASES; ETHNIC GROUPS; HAPLOTYPES; HUMANS; INTRONS; ISOENZYMES; MIXED FUNCTION OXYGENASES; POLYMORPHISM, GENETIC; UNTRANSLATED REGIONS; VARIATION (GENETICS);

STAPHYLOCOCCUS PHAGE 3A;

EID: 3543042787     PISSN: 14622416     EISSN: None     Source Type: Journal    
DOI: 10.1517/phgs.5.3.243.29833     Document Type: Review

References (163)

1. Shimada T, Yamazaki H, Mimura M, Inui Y, Guengerich FP: Interindividual variations in human liver cytochrome P450 enzymes involved in the oxidation of drugs, carcinogens and toxic chemicals: studies with liver microsomes of 30 Japanese and 30 Caucasians. J. Pharmacol. Exp. Ther. 270(1), 414-423 (1994).
2. Kolars JC, Schmiedlin-Ren P, Schuetz JD, Fang C, Watkins PB: Identification of ripampicin-inducible P450IIIA4 (CYP3A4) in human small-bowel enterocytes. J. Clin. Invest. 90(5), 1871-1878 (1992).
3. Kolars JC, Lown KS, Schmiedlin-Ren P et al.: CYP3A gene expression in human gut epithelium. Pharmacogenetics 4(5), 247-259 (1994).
4. Lown KS, Kolars JC, Thummel KE et al.: Interpatient heterogeneity in expression of CYP3A4 and CYP3A5 in small bowel: lack of prediction by the erythromycin breath test. Drug Metab. Dispos. 22(6), 947-955 (1994).
5. Paine MF, Khaeighi M, Fisher JM et al.: Characterization of interintestinal and intraintestinal variation in human CYP3A-dependent metabolism. J. Pharmacol. Exp. Ther. 283(3), 1552-1562 (1997).
6. Koch I, Weil R, Wolbold R et al.: Interindividual variability and tissue-specificity in the expression of cytochrome P450 3A mRNA. Drug Metab. Dispos. 30(10), 1108-1114 (2002).
7. Lin YS, Dowling ALS, Quigley SD et al.: Co-regulation of CYP3A4 and CYP3A5 and contribution to hepatic and intestinal midazolam metabolism. Mol. Pharmacol. 62(1), 162-172 (2002).
8. Schuetz EG, Schuetz JD, McLean Grogan W et al.: Expression of cytochrome P450 3A in amphibian, rat, and human kidney. Arch. Biochem. Biophys. 294(1), 206-214 (1992).
9. Haehner BD, Gorski JC, Vanden Branden M et al.: Biomodal distribution of renal cytochrome P450 activity in humans. Mol. Pharmacol. 50(1), 52-59 (1996).
10. Givens RC, Lin YS, Dowling ALS et al.: CYP3A5 genotype predicts renal CYP3A activity and blood pressure in healthy adults. J. Appl. Physiol. 95(3), 1297-1300 (2003).
11. Cholerton S, Daly AK, Idle JR: The role of individual human cytochromes P450 in drug metabolism and clinical response. Trends Pharmacol. Sci. 13(12), 434-439 (1992).
12. Li AP, Kaminski DL, Rasmussen A: Substrates of human hepatic cytochrome P450 3A4. Toxicology 10(1), 1-8 (1995).
13. Thummel KE, Wilkinson GR: In vitro and in vivo drug interaction involving human CYP3A. Ann. Rev. Pharmacol. Toxicol. 38, 389-430 (1998).
14. Guengerich FP: Cytochrome P450 3A4: regulation and role in drug metabolism. Ann. Rev. Pharmacol. Toxicol. 39, 1-17 (1999).
15. Wrighton SA, Schuetz EG, Thummel KE, Shen DD, Korzekwa KR, Watkins PB: The human CYP3A subfamily: practical considerations. Drug Metab. Rev. 32(3-4), 339-361 (2000).
16. Rendic S: Summary of information on human CYP enzymes: human P450 metabolism data. Drug Metab. Rev. 34(1-2), 83-448 (2002).
17. Ekins S, Stresser DM, Williams JA: In vitro and pharmacophore insights into CYP3A enzymes. Trends Pharmacol. Sci. 24(4), 161-166 (2003).
18. Özdemir V, Kalow W, Tang BK et al.: Evaluation of the genetic component of variability in CYP3A4 activity: a repeated drug administration method. Pharmacogenetics 10(5), 373-388 (2000).
19. Lamba JK, Lin YS, Schuetz EG, Thummel KE: Genetic contribution to variable human CYP3A-mediated metabolism. Adv. Drug Deliv. Rev. 54(10), 1271-1294 (2002).
20. Patki KC, von Moltke LL, Greenblatt DJ: In vitro metabolism of midazolam, triazolam, nifedipine, and testosterone by human liver microsomes and recombinant cytochrome P450: role of CYP3A4 and CYP3A5. Drug Metab. Dispos. 31(7), 938-944 (2003).
21. Williams JA, Ring BJ, Cantrell VE et al.: Comparative metabolic capacities of CYP3A4, CYP3A5, and CYP3A7. Drug Metab. Dispos. 30(8), 883-891 (2002).
22. Schuetz JD, Beach DL, Guzelian PS: Selective expression of cytochrome P450 CYP3A mRNAs in embryonic and adult human liver. Pharmacogenetics 4(1), 11-20 (1994).
23. Westlind A, Malmebo S, Johnsson I et al.: Cloning and tissue distribution of a novel human cytochrome P450 of the CYP3A subfamily, CYP3A43. Biochem. Biophys. Res. Commun. 281(5), 1349-1355 (2001).
24. Domanski TL, Finta C, Halpert JR, Zaphiropoulos PG: cDNA cloning and initial characterization of CYP3A43, a novel human cytochrome P450. Mol. Pharmacol. 59(2), 386-392 (2001).
25. Kuehl P, Zhang J, Lin Y et al.: Sequence diversity in CYP3A promoters and characterization of the genetic basis of polymorphic CYP3A5 expression. Nat. Genet. 27(4), 383-391 (2001).
26. Hustert E, Haberl M, Burk O et al.: The genetic determinants of the CYP3A5 polymorphism. Pharmacogenetics 11(9), 773-779 (2001).
27. Balram C, Zhou Q, Cheung YB, Lee EJD: CYP3A5*3 and *6 single nucleotide polymorphisms in three distinct Asian populations. Eur. J. Clin. Pharmacol. 59(2), 123-126 (2003).
28. Floyd MD, Gervasini G, Masica AL et al.: Genotype-phenotype associations for common CYP3A4 and CYP3A5 variants in the basal and induced metabolism of midazolam in European- and African-American men and women. Pharmacogenetics 13(10), 595-606 (2003).
29. Kadlubar FF, Berkowitz GS, Delongchamp RR et al.: The CYP3A4*1B variant is related to the onset of puberty, a known risk factor for the development of breast cancer. Cancer Epidemiol. Biomark. Prev. 12(4), 327-331 (2003).
30. Lee S-J, Usmani KA, Chanas B et al.: Genetic findings and functional studies of human CYP3A5 single nucleotide polymorphisms in different ethnic groups. Pharmacogenetics 13(8), 461-472 (2003).
31. Plummer SJ, Conti DV, Paris PL, Curran AP, Casey G, Witte JS: CYP3A4 and CYP3A5 genotypes, haplotypes, and risk of prostate cancer. Cancer Epidemiol. Biomark. Prev. 12(9), 928-932 (2003).
32. Blanco JG, Edick MJ, Hancock ML et al.: Genetic polymorphisms in CYP3A5, CYP3A4 and NQO1 in children who developed therapy-related myeloid malignancies. Pharmacogenetics 12(8), 605-611 (2002).
33. Brooks BA, McBride OW, Dolphin CT et al.: The gene CYP3 encoding P450PCN1 (nifedipine oxidase) is tightly linked to the gene COL1A2 encoding collagen Type 1 alpha on 7q21-q22. 1. Am. J. Hum. Genet. 43(3), 280-284 (1988).
34. Spurr NK, Gough AC, Stevenson K, Wolf CR: The human cytochrome P450 CYP3A locus: assignment to chromosome 7q22-qter. Hum. Genet. 81(2), 171-174 (1989).
35. Inoue K, Inazawa J, Nakagawa H et al.: Assignment of the human cytochrome P450 nifedipine oxidase gene (CYP3A4) to chromosome 7 at band q22.1 by flourescence in situ hybridization. Jpn. J. Hum. Genet. 37, 133-138 (1992).
36. Nelson DR, Koymans L, Kamataki T et al.: P450 superfamily: update on new sequences, gene mapping, accession numbers and nomenclature. Pharmacogenetics 6(1), 1-42 (1996).
37. Gellner K, Eiselt R, Hustert E et al.: Genomic organization of the human CYP3A locus: identification of a new, inducible CYP3A gene. Pharmacogenetics 11(2), 111-121 (2001).
38. Finta C, Zaphiropoulos PG: Intergenic mRNA molecules resulting from trans-splicing. J. Biol. Chem. 277(8), 5882-5890 (2002).
39. Nelson DR, Zeldin DC, Hoffman SMG, Maltais LJ, Wain HM, Nebert DW: Comparison of cytochrome P450 (CYP) genes from the mouse and human genomes, including nomenclature recommendations for genes, pseudogenes and alternative-splice variants. Pharmacogenetics 14(1), 1-18 (2004).
40. Finta C, Zaphiropoulos PG: The human cytochrome P450 3A locus: gene evolution by capture of downstream exons. Gene 260(1-2), 13-23 (2000).
41. Hashimoto H, Toide K, Kitamura R et al.: Gene structure of CYP3A4, an adult-specific form of cytochrome P450 in human livers, and its transcription control. Eur. J. Biochem. 218(2), 585-595 (1993).
42. Aoyama T, Yamano S, Waxman DJ et al.: Cytochrome P450 hPCN3, a novel cytochrome P450 IIIA gene product that is differentially expressed in adult human liver: cDNA and deduced amino acid sequence and distinct specificities of cDNA-expressed hPCN1 and hPCN3 for the metabolism of steroid hormones and cyclosporine. J. Biol. Chem. 264(18), 10388-10395 (1989).
43. Schuetz JD, Molowa DT, Guzelian PS: Characterization of a cDNA encoding a new member of the glucocorticoid-responsive cytochrome P450 in human liver. Arch. Biochem. Biophys. 274(2), 355-365 (1989).
44. Jounaïdi Y, Hyrailles V, Gervot L, Maurel P: Detection of a CYP3A5 allelic variant: a candidate for the polymorphic expression of the protein? Biochem. Biophys. Res. Commun. 221(2), 466-470 (1996).
45. Shih PS, Huang JD: Pharmacokinetics of midazolam and 1′-hydroxymidazolam in Chinese with different CYP3A5 genotypes. Drug Metab. Dispos. 30(12), 1491-1496 (2002).
46. van Schaik RHN, van der Heiden IP, van den Anker JN, Lindemans J: CYP3A5 variant allele frequencies in Dutch Caucasians [published erratum appears in Clin. Chem. 49(3), 528 (2003)]. Clin. Chem. 48(10), 1668-1671 (2002).
47. Chou F-C, Tzeng S-J, Huang J-D: Genetic polymorphism of cytochrome P450 3A5 in Chinese. Drug Metab. Dispos. 29(9), 1205-1209 (2001).
48. Fukuen S, Fukuda T, Maune H et al.: Novel detection assay by PCR-RFLP and frequency of the CYP3A5 SNPs, CYP3A5*3 and *6, in a Japanese population. Pharmacogenetics 12(4), 331-334 (2002).
49. Liu T-C, Lin S-F, Chen T-P, Chang J-G: Polymorphism analysis of CYP3A5 in myeloid leukemia. Oncol. Reports 9(2), 327-329 (2002).
50. Hesselink DA, van Schaik RHN, van der Heiden IP et al.: Genetic polymorphisms of the CYP3A4, CYP3A5, and MDR-1 genes and pharmacokinetics of the calcineurin inhibitors cyclosporine and tacrolimus. Clin. Pharmacol. Ther. 74(3), 245-254 (2003).
51. Yates CR, Zhang W, Song P et al.: The effect of CYP3A5 and MDR1 polymorphic expression on cyclosporine oral disposition in renal transplant patients. J. Clin. Pharmacol. 43(6), 555-564 (2003).
52. Song P, Dirks N, Gaber AO et al.: Detection of CYP3A5*3 and *6 using real-time PCR. Clin. Pharmacol. Ther. 71(2), P103 (2002) (Abstract).
53. King BP, Leathart JBS, Mutch E, Williams FM, Daly AK: CYP3A5 phenotype-genotype correlations in a British population. Br. J. Clin. Pharmacol. 55(6), 625-629 (2003).
54. Thervet E, Anglicheau D, King B et al.: Impact of cytochrome P450 3A5 genetic polymorphism on tacrolimus doses and concentration-to-dose ratio in renal transplant recipients. Transplantation 76(8), 1233-1235 (2003).
55. Weiss J, Haefeli WE: Genotyping of the A6986G polymorphism of CYP3A5. Br. J. Clin. Pharmacol. (2004) (In Press).
56. Hiratsuka M, Takekuma Y, Endo N et al.: Allele and genotype frequencies of CYP2B6 and CYP3A5 in the Japanese population. Eur. J. Clin. Pharmacol. 58(6), 417-421 (2002).
57. Westlind-Johnsson A, Malmebo S, Johansson A et al.: Comparative analysis of CYP3A expression in human liver suggests only a minor role for CYP3A5 in drug metabolism. Drug Metab. Dispos. 31(6), 755-761 (2003).
58. Dally H, Edler L Jäger B et al.: The CYP3A4*1B allele increases risk for small cell lung cancer: effect of gender and smoking dose. Pharmacogenetics 13(10), 607-618 (2003).
59. Rogan PK, Svojanovsky S, Leeder JS: Information theory-based analysis of CYP2C19, CYP2D6 and CYP3A5 splicing mutations. Pharmacogenetics 13(4), 207-218 (2003).
60. Xie H-G, Kim RB: Genetic polymorphisms of cytochrome P450s and drug transporters and infectious disease management. In: Molecular Microbiology: Diagnostic Principles and Practice (Chapter 49). Persing DH, Tenover FC, Versalovic J et al. (Eds), ASM Press, Washington, DC, 655-669 (2004).
61. Zheng H, Webber S, Zeevi A et al.: Tacrolimus dosing in pediatric heart transplant patients is related to CYP3A5 and MDR1 gene polymorphisms. Am. J. Transplant. 3(4), 477-483 (2003).
62. Aplenc R, Glatfelter W, Han P et al.: CYP3A genotypes and treatment response in paediatric acute lymphoblastic leukaemia. Br. J. Haematol. 122(2), 240-244 (2003).
63. Wadelius M, Sörlin K, Wallerman O et al.: Warfarin sensitivity related to CYP2C9, CYP3A5, ABCB1 (MDR1) and other factors. Pharmacogenomics J. 4(1), 40-48 (2004).
64. Jounaïdi Y, Guzelian PS, Maurel P, Vilarem MJ: Sequence of the 5′-flanking region of CYP3A5: comparative analysis with CYP3A4 and CYP3A7. Biochem. Biophys. Res. Commun. 205(3), 1741-1747 (1994).
65. Paulussen A, Lavrijsen K, Bohets H et al.: Two linked mutations in transcriptional regulatory elements of the CYP3A5 gene constitute the major genetic determinant of polymorphic activity in humans. Pharmacogenetics 10(5), 415-424 (2000).
66. Nakamura T, Saito Y, Murayama N et al.: Apparent low frequency of sequence variability within the proximal promoter region of the cytochrome P450 (CYP) 3A5 gene in established cell lines from Japanese individuals. Biol. Pharm. Bull. 24(8), 954-957 (2001).
67. Zhu B, Chen G-L, Chen X-P et al.: Genotype of CYP3AP1 associated with CYP3A activity in Chinese Han population. Acta Pharmacol. Sinica 23(6), 567-571 (2002).
68. Lehmann JM, McKee DD, Watson MA, Willson TM, Moore JT, Kliewer SA: The human orphan nuclear receptor PXR is activated by compounds that regulate CYP3A4 gene expression and cause drug interactions. J. Clin. Invest. 102(5), 1016-1023 (1998).
69. Goodwin B, Hodgson E, Liddle C: The orphan human pregnane X receptor mediates the transcriptional activation of CYP3A4 by rifampicin through a distal enhancer module. Mol. Pharmacol. 56(6), 1329-1339 (1999).
70. Goodwin B, Redinbo MR, Kliewer SA: Regulation of CYP3A gene transcription by the pregnane X receptor. Ann. Rev. Pharmacol. Toxicol. 42, 1-23 (2002).
71. Goodwin B, Hodgson E, D'Costa DJ, Robertson GR, Liddle C: Transcriptional regulation of the human CYP3A4 gene by the constitutive androstane receptor. Mol. Pharmacol. 62(2), 359-365 (2002).
72. Tirona RG, Lee W, Leake BF et al.: The orphan nuclear receptor HNFα determines PXR- and CAR-mediated xenobiotic induction of CYP3A4. Nat. Med. 9(2), 220-224 (2003).
73. Rae JM, Johnson MD, Lippman ME, Flockhart DA: Rifampin is a selective, pleiotropic inducer of drug metabolism genes in human hepatocytes: studies with cDNA and oligonucleotide expression arrays. J. Pharmacol. Exp. Ther. 299(3), 849-857 (2001).
74. Wrighton SA, Ring BJ, Watkins PB, Vanden Branden M: Identification of a polymorphically expressed member of the human cytochrome P450 III family. Mol. Pharmacol. 36(1), 97-105 (1989).
75. Schuetz EG, Scheutz JD, Strom SC et al.: Regulation of human liver cytochrome P450 in family 3A in primary and continuous culture of human hepatocytes. Hepatology 18(5), 1254-1262 (1993).
76. Gervot L, Carriere V, Coster P et al.: CYP3A5 is the major P450 3A expressed in human colon and colonic cell lines. Environ. Toxicol. Pharmacol. 2(4), 381-388 (1996).
77. Hukkanen J, Vaisanen T, Lassila A et al.: Regulation of CYP3A5 by glucocorticoids and cigarette smoke in human lung-derived cells. J. Pharmacol. Exp. Ther. 304(2), 745-752 (2003).
78. Xie H-G, Kim RB, Wood AJJ, Stein CM: Molecular basis of ethnic differences in drug disposition and response. Ann. Rev. Pharmacol. Toxicol. 41, 815-850 (2001).
79. Evans WE, McLeod HL: Pharmcogenomics - drug disposition, drug targets, and side effects. N. Engl. J. Med. 348(6), 538-549 (2003).
80. Weinshilboum R: Inheritance and drug response. N. Engl. J. Med. 348(6), 529-537 (2003).
81. Nebert DW, Menon AG: Reply to Kalow et al.: Pharmacogenomics J. 1(4), 235-236 (2001).
82. Kalow W, Ozdemir V, Tothfalusi L: Multigenic traits and risk assessment in pharmacology: a population approach. Pharmacogenomics J. 1(4), 234-236 (2001).
83. Rothstein MA, Epps PG: Pharmacogenomics and the (ir)relevance of race. Pharmacogenomics J. 1(2), 104-108 (2001).
84. Kalow W: Medical practice, race, and drug use. Clin. Pharmacol. Ther. 73(1), 132-134 (2003).
85. Burchard EG, Ziv E, Coyle N et al.: The importance of race and ethnic background in biomedical research and clinical practice. N. Engl. J. Med. 348(12), 1170-1175 (2003).
86. Cooper RS, Kaufman J, Ward R: Race and genomics. N. Engl. J. Med. 348(12), 1166-1170 (2003).
87. Erickson AK: Ethnicity puts clinical trials to the test. Nat. Med. 9(8), 983 (2003).
88. Haga SB, Venter JC: FDA races in wrong direction. Science 301(5632), 466 (2003).
89. Holden C: Race and medicine. Science 302(5645), 594-596 (2003).
90. Kaplan JB, Bennett T: Use of race and ethnicity in biomedical publication. JAMA 289(20), 2709-2716 (2003).
91. Lee SS: Race, distributive justice and the promise of pharmacogenomics. Am. J. Pharmacogenomics 3(6), 385-392 (2003).
92. Kalow W, Bertilsson L: Interethnic factors affecting drug response. Adv. Drug Res. 23, 1-53 (1994).
93. Xie H-G, Prasad HC, Kim RB, Stein CM: CYP2C9 allelic variants: ethnic distribution and functional significance. Adv. Drug Deliv. Rev. 54(10), 1257-1270 (2002).
94. Department of Health and Human Services, FDA: Draft guidance for industry on the collection of race and ethnicity data in clinical trails for FDA regulated products. Fed. Regist. 68(10), 30 (2003).
95. D'Agostino RB, Weintraub M: Meta-analysis: a method for synthesizing research. Clin. Pharmacol. Ther. 58(6), 605-616 (1995).
96. Xie H-G, Stein CM, Kim RB, Wilkinson GR, Flockhart DA, Wood AJJ: Allelic, genotypic and phenotypic distributions of S-mephenytoin 4′-hydroxylase (CYP2C19) in healthy Caucasian populations of European descent throughout the world. Pharmacogenetics 9(5), 539-549 (1999).
97. Wojnowski L, Hustert E, Klein K et al.: Re: Modification of clinical presentation of prostate tumors by a novel genetic variant in CYP3A4. J. Natl. Cancer Inst. 94(8), 630-631 (2002).
98. Wacher VJ, Wu C-Y Benet LZ: Overlapping substrate specificities and tissue distribution of cytochrome P450 3A and P-glycoprotein: implications for drug delivery and activity in cancer therapy. Mol. Carcinogen. 13(3), 129-134 (1995).
99. Schuetz EG, Beck WT, Schuetz JD: Modulators and substrates of P-glycoprotein and cytochrome P4503A coordinately up-regulate these proteins in human colon carcinoma cells. Mol. Pharmacol. 49(2), 311-318 (1996).
100. Kim RB, Wandel C, Leake B et al.: Interrelationship between substrates and inhibitors of human CYP3A and P-glycoprotein. Pharm. Res. 16(3), 408-414 (1999).
101. Kim RB, Wilkinson GR: Pharmacogenetics of drug transporters. In: Pharmcogenomics. Kalow W, Meyer UA, Tyndale RE (Eds), Marcel Dekker, Inc., New York, 81-108 (2001).
102. Marzolini C, Paus E, Buclin T, Kim RB: Polymorphisms in human MDR1 (P-glycoprotein): recent advances and clinical relevance. Clin. Pharmacol. Ther. 75(1), 13-33 (2004).
103. Kim RB: Pharmacogenetics of CYP enzymes and drug transporters: remarkable recent advances. Adv. Drug Deliv. Rev. 54(10), 1241-1242 (2002).
104. Kim RB: Transporters and xenobiotic disposition. Toxicology 181-182, 291-297 (2002).
105. Schuetz EG, Schinkel AH, Relling MV, Schuetz JD: P-glycoprotein: a major determinant of rifampicin-inducible expression of cytochrome P4503A in mice and humans. Proc. Natl. Acad. Sci. USA 93(9), 4001-4005 (1996).
106. Lan LB, Dalton JT, Schuetz EG: Mdr1 limits CYP3A metabolism in vivo. Mol. Pharmacol. 58(4), 863-869 (2000).
107. Cummins CL, Wu C-Y, Benet LZ: Sex-related differences in the clearance of cytochrome P450 3A4 substrates may be caused by P-glycoprotein. Clin. Pharmacol. Ther. 72(5), 474-489 (2002).
108. Wu C-Y, Benet LZ: Disposition of tacrolimus inisolated perfused rat liver: influence of troleandomycin, cyclosporine, and GG918. Drug Metab. Dispos. 31(11), 1292-1295 (2003).
109. Benet LZ, Cummins CL, Wu CY: Transporter-enzyme interactions: implications for predicting drug-drug interactions from in vitro data. Curr. Drug Metab. 4(5), 393-398 (2003).
110. Meisel C, Roots I, Cascorbi I, Brinkmann U, Brockmöller J: How to manage individualized drug therapy: application of pharmacogenetic knowledge of drug metabolism and transport. Clin. Chem. Lab. Med. 38(9), 869-876 (2000).
111. Chowbay B, Cumaraswamy S, Cheung YB, Zhou Q, Lee EJD: Genetic polymorphisms in MDR1 and CYP3A4 genes in Asians and the influence of MDR1 haplotypes on cyclosporin disposition in heart transplant recipients. Pharmacogenetics 13(2), 89-95 (2003).
112. Hentze MW, Kulozik AE: A perfect message: RNA surveillance and nonsense-mediated decay. Cell 96(3), 307-310 (1999).
113. Sun X, Maquat LE: mRNA surveillance in mammalian cells: the relationship between introns and translation termination. RNA 6(1), 1-8 (2000).
114. Frischmeyer PA, van Hoof A, O'Donnell K, Guerrerio AL, Parker R, Dietz HC: An mRNA surveillance mechanism that eliminates transcripts lacking termination codons. Science 295(5563), 2258-2261 (2002).
115. Hillman RT, Green RE, Brenner SE: An unappreciated role for RNA surveillance. Genome Biol. 5(2), R8.1-R8.16 (2004).
116. Williams JA, Cook J, Hurst SI: A significant drug-metabolizing role for CYP3A5? Drug Metab. Dispos. 31(12), 1526-1531 (2003).
117. Gorski JC, Hall SD, Jones DR, Vanden Branden M, Wrighton SA: Regioselective biotransformation of midazolam by members of the human cytochrome P450-3A (CYP3A) subfamily. Biochem. Pharmacol. 47(9), 1643-1653 (1994).
118. Kronbach T, Mathys D, Umeno M, Gonzalez FJ, Meyer UA: Oxidation of midazolam and triazolam by human liver microsome P450IIIA4. Mol. Pharmacol. 36(1), 89-96 (1989).
119. Dally H, Bartsch H, Edler L et al.: Incomplete linkage of CYP3AP1 and CYP3A5 genotypes. Drug Metab. Rev. 35(Suppl. 1), 130 (2003) (Abstract).
120. Backman JT, Kivistö KT, Olkkola KT, Keuvonen PJ: The area under the plasma concentration-time curve for oral midazolam is 400-fold larger during treatment with itraconazole than with rifampicin. Eur. J. Clin. Pharmacol. 54(1), 53-58 (1998).
121. Lin YS, Lockwood GF, Graham MA et al.: In-vivo phenotyping for CYP3A by a single-point determination of midazolam plasma concentration. Pharmacogenetics 11 (12), 781-791 (2001).
122. Xie R, Knuth DM, Tan L et al.: Fexofenadine and midazolam disposition in relation to genetic polymorphisms of CYP3A, PXR and P-glycoprotein. Clin. Pharmacol. Ther. 73(2), P19 (2003) (Abstract). (Some data were unpublished in this abstract but presented in their meeting poster).
123. Goh B-C, Lee S-C, Wang L-Z et al.: Explaining interindividual variability of docetaxel pharmacokinetics and pharmacodynamics in Asians through phenotyping and genotyping strategies. J. Clin. Oncol. 20(17), 3683-3690 (2002).
124. Wrighton SA, Brian WR, Sari MA et al.: Studies on the expression and metabolic capabilities of human liver cytochrome P450 IIIA5 (HLp3). Mol. Pharmacol. 38(2), 207-213 (1990).
125. Fukuda T, Onishi S, Fukuen S et al.: CYP3A5 genotype did not impact on nifedipine disposition in healthy volunteers. Pharmacogenomics J. 4(1), 34-39 (2004).
126. Ahsan CH, Renwick AG, Macklin B, Challenor VF, Waller DG, George CF: Ethnic differences in the pharmacokinetics of oral nifedipine. Br. J. Clin. Pharmacol. 31(4), 399-403 (1991).
127. Ahsan CH, Renwick AG, Waller DC, Challenor VF, George CF, Amanullah M: The influence of dose and ethnic origin on the pharmacokinetics of nifedipine. Clin. Pharmacol. Ther. 54(3), 329-338 (1993).
128. Sowunmi A, Rashid TJ, Akinyinka OO, Renwick AG: Ethnic differences in nifedipine kinetics: comparisons between Nigerians, Caucasians and South Asians. Br. J. Clin. Pharmacol. 40(5), 489-493 (1995).
129. Yu KS, Bae KS, Sohn JH et al.: Ethnic differences in pharmacokinetics of nifedipine and erythromycin. Clin. Pharmacol. Ther. 67(2), 161 (2000) (Abstract) .
130. Lin Y, Anderson GD, Kantor E, Ojemann LM, Wilensky AJ: Differences in the urinary excretion of 6-β-hydroxycortisol/cortisol between Asian and Caucasian women. J. Clin. Pharmacol. 39(6), 578-582 (1999).
131. Wandel C, Witte JS, Hall JM, Stein CM, Wood AJJ, Wilkinson GR: CYP3A activity in African-Americans and European men: population differences and functional effect of the CYP3A4*1B 5′ -promoter region polymorphism. Clin. Pharmacol. Ther. 68(1), 82-91 (2000).
132. Tateishi T, Watanabe M, Nakura H et al.: CYP3A activity in European American and Japanese men using midazolam as an in vivo probe. Clin. Pharmacol. Ther. 69(5), 333-339 (2001).
133. Poland RA, Lin K-M, Nuccio C, Wilkinson GR: Cytochrome P450 2E1 and 3A activities do not differ between Mexicans and European Americans. Clin. Pharmacol. Ther. 72(3), 288-293 (2002).
134. Spencer CM, Goa KL, Gillis JC: Tacrolimus: an update of its pharmacology and clinical efficacy in the management of organ transplantation. Drugs 54(6), 925-975 (1997).
135. Dunn CJ, Wagstaff AJ, Perry CM, Plosker GL, Goa KL: Cyclosporine: an updated review of the pharmacokinetic properties, clinical efficacy and tolerability of a microemulsion-based formulation (neoral) in organ transplantation. Drugs 61(13), 1957-2016 (2001).
136. Jusko WJ, Thomson AW, Fung J et al.: Consensus document: therapeutic monitoring of tacrolimus (FK-506). Ther. Drug Monit. 17(6), 606-614 (1995).
137. Lindholm A: Cyclosporine A: clinical experience and therapeutic drug monitoring. Ther. Drug Monit. 17(6), 631-637 (1995).
138. Klupp J, Holt DW, van Gelder T: How pharmacokinetic and pharmacodynamic drug monitoring can improve outcome in solid organ transplant recipients. Transplant Immunol. 9(2-4), 211-214 (2002).
139. Oellerich M, Armstrong VW: Two-hour cyclosporine concentration determination: an appropriate tool to monitor neoral therapy? Ther. Drug Monit. 24(1), 40-46 (2002).
140. Lampen A, Christians U, Guengerich FP et al.: Metabolism of the immunosuppressant tacrolimus in the small intestine: cytochrome P450, drug interactions and interindividual variability. Drug Metab. Dispos. 23(12), 1315-1324 (1995).
141. Kronbach T, Fischer V, Meyer UA: Cyclosporine metabolism in human liver: identification of a cytochrome P450 III gene family as the major cyclosporine-metabolizing enzyme explains interactions of cyclosporine with other drugs. Clin. Pharmacol. Ther. 43(6), 630-635 (1988).
142. Sattler M, Guengerich FP, Yun CH, Christians U, Sewing KF: Cytochrome P450 3A enzymes are responsible for biotransformation of FK506 and rapamycin in man and rat. Drug Metab. Dispos. 20(5), 753-761 (1992).
143. Min DI, Ellingrod VL: Association of the CYP3A4*1B 5′-flanking region polymorphism with cyclosporine pharmacokinetics in healthy subjects. Ther. Drug Monit. 25(3), 305-309 (2003).
144. Haufroid V, Mourad M, van Kerckhove V et al.: The effect of CYP3A5 and MDR1 (ABCB1) polymorphisms on cyclosporine and tacrolimus dose requirements and though blood levels in stable renal transplant patients. Pharmacogenetics 14(3), 147-154 (2004).
145. MacPhee IAM, Fredericks S, Tai T et al.: Tacrolimus pharmacogenetics: polymorphisms associated with expression of cytochrome P4503A5 and P-glycoprotein correlate with dose requirement. Transplantation 74(11), 1486-1489 (2002).
146. Saeki T, Ueda K, Tanisawara Y, Hori R, Komano T: Human P-glycoprotein transports cyclosporin A and FK506. J. Biol. Chem. 268(9), 6077-6080 (1993).
147. Fredericks S, Holt DW, MacPhee IAM: The pharmacogenetics of immunosuppression for organ transplantation: a route to individualization of drug administration. Am. J. Pharmacogenomics 3(5), 291-301 (2003).
148. Andrews PA, Sen M, Chang RW: Racial variation in dosage requirements of tacrolimus. Lancet 348(9039), 1446 (1996).
149. Mancinelli LM, Frassetto L, Floren LC et al.: The pharmacokinetics and metabolite disposition of tacrolimus: a comparison across ethnic groups. Clin. Pharmacol. Ther. 69(1), 24-31 (2001).
150. Weinberger MH: Salt sensitivity of blood pressure in humans. Hypertension 27(3, part 2), 481-490 (1996).
151. Langaee TY, Givens RC, Sloan A, Watkins PB, Johnson JA: Association of CYP3A5*3, *6, and *7 polymorphisms with hypertension. Clin. Pharmacol. Ther. 75(2), P13 (2004) (Abstract).
152. Rebbeck TR, Jaffe JM, Walker AH, Wein AJ, Malkowicz SB: Modiciation of clinical presentation of prostate tumors by a novel genetic variant in CYP3A4. J. Natl. Cancer Inst. 90(16), 1225-1229 (1998).
153. Paris PL, Kupelian PA, Hall JM et al.: Association between a CYP3A4 genetic variant and clinical presentation in African-American prostate cancer patients. Cancer Epidemiol. Biomark. Prev. 8(10), 901-905 (1999).
154. Ball SE, Scatina J, Kao J et al.: Population distribution and effects on drug metabolism of a genetic variant in the 5′ promoter region of CYP3A4. Clin. Pharmacol. Ther. 66(3), 288-294 (1999).
155. Yamakoshi Y, Kishimoto T, Sugimura K, Kawashima H: Human prostate CYP3A5: identification of a unique 5′-untranslated sequence and characterization of purified recombinant protein. Biochem Biophys. Res. Commun. 260(3), 676-681 (1999).
156. Finnstrom N, Bjelfman C, Soderstrom TG et al.: Detection of cytochrome P450 mRNA transcripts in prostate samples by RT-PCR. Eur. J. Clin. Invest. 31(10), 880-886 (2001).
157. Kittles RA, Chen W, Panguluri RK et al.: CYP3A4-V and prostate cancer in African Americans: causal or confounding association because of population stratification? Hum. Genet. 111, 553-560 (2002).
158. Ziv E, Burchard EG: Human population structure and genetic association studies. Pharmacogenomics 4(4), 431-441 (2003).
159. Greenlee RT, Murray T, Bolden S, Wingo PA: Cancer statistics, 2000. CA Cancer J. Clin. 50(1), 7-33 (2000).
160. Kivistö KT, Griese E-U, Fritz P et al.: Expression of cytochrome P450 3A enzymes in human lung: a combined RT-PCR and immunohistochemical analysis of normal tissue and lung tumours. Naunyn-Schmiedeberg's Arch. Pharmacol. 353(2), 207-212 (1996).
161. Anttila S, Hukkanen J, Hakkola J et al.: Expression and location of CYP3A4 and CYP3A5 in human lung. Am. J. Respir. Cell Mol. Biol. 16(3), 242-249 (1997).
162. Piipari R, Savela K, Nurminen T et al.: Expression of CYP1A1, CYP1B1 and CYP3A, and polycyclic aromatic hydrocarbon-DNA adduct formation in bronchoalveolar macrophages of smokers and non-smokers. Int. J. Cancer 86(5), 610-616 (2000).
163. Yeh KT, Chen JC, Chen CM, Wang YF, Lee TP, Chang JG: CYP3A5*1 is an inhibitory factor for lung cancer in Taiwanese [in Chinese]. Kaohsiung J. Med. Sci. 19(5), 201-207 (2003).